• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by Vicarious Surgical Inc.

    10/15/25 4:30:50 PM ET
    $RBOT
    Industrial Specialties
    Health Care
    Get the next $RBOT alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM D

    Notice of Exempt Offering of Securities

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
       None
    Entity Type
    0001812173
    D8 Holdings Corp.
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    Vicarious Surgical Inc.
    Jurisdiction of Incorporation/Organization
    DELAWARE
    Year of Incorporation/Organization
    X Over Five Years Ago
       Within Last Five Years (Specify Year)
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    Vicarious Surgical Inc.
    Street Address 1 Street Address 2
    78 FOURTH AVENUE
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    WALTHAM MASSACHUSETTS 02451 (617) 868-1700

    3. Related Persons

    Last Name First Name Middle Name
    From Stephen
    Street Address 1 Street Address 2
    78 Fourth Avenue
    City State/Province/Country ZIP/PostalCode
    Waltham MASSACHUSETTS 02451
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):

    Chief Executive Officer
    Last Name First Name Middle Name
    Sachs Adam
    Street Address 1 Street Address 2
    78 Fourth Avenue
    City State/Province/Country ZIP/PostalCode
    Waltham MASSACHUSETTS 02451
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):

    President
    Last Name First Name Middle Name
    Romano Sarah
    Street Address 1 Street Address 2
    78 Fourth Avenue
    City State/Province/Country ZIP/PostalCode
    Waltham MASSACHUSETTS 02451
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):

    Chief Financial Officer
    Last Name First Name Middle Name
    Khalifa Sammy
    Street Address 1 Street Address 2
    78 Fourth Avenue
    City State/Province/Country ZIP/PostalCode
    Waltham MASSACHUSETTS 02451
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):

    Chief Technology Officer
    Last Name First Name Middle Name
    Carr-Brendel Victoria
    Street Address 1 Street Address 2
    78 Fourth Avenue
    City State/Province/Country ZIP/PostalCode
    Waltham MASSACHUSETTS 02451
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Clark Randy
    Street Address 1 Street Address 2
    78 Fourth Avenue
    City State/Province/Country ZIP/PostalCode
    Waltham MASSACHUSETTS 02451
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Ho David
    Street Address 1 Street Address 2
    78 Fourth Avenue
    City State/Province/Country ZIP/PostalCode
    Waltham MASSACHUSETTS 02451
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Huss Beverly
    Street Address 1 Street Address 2
    78 Fourth Avenue
    City State/Province/Country ZIP/PostalCode
    Waltham MASSACHUSETTS 02451
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Ahmad Fuad
    Street Address 1 Street Address 2
    78 Fourth Avenue
    City State/Province/Country ZIP/PostalCode
    Waltham MASSACHUSETTS 02451
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Doherty Joseph
    Street Address 1 Street Address 2
    78 Fourth Avenue
    City State/Province/Country ZIP/PostalCode
    Waltham MASSACHUSETTS 02451
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
       Biotechnology
       Health Insurance
       Hospitals & Physicians
       Pharmaceuticals
    X Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
      
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
    X Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2025-10-09    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
       Yes X No

    9. Type(s) of Securities Offered (select all that apply)

    X Equity    Pooled Investment Fund Interests
       Debt    Tenant-in-Common Securities
    X Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
    X Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security    Other (describe)

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
       Yes X No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number    None
    Lake Street Capital Markets, LLC 000164447
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    None None
    Street Address 1 Street Address 2
    121 South 8th Street Suite 1000
    City State/Province/Country ZIP/Postal Code
    Minneapolis MINNESOTA 55402
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US
    NEW YORK

    13. Offering and Sales Amounts

    Total Offering Amount $11,730,000 USD
    or    Indefinite
    Total Amount Sold $11,730,000 USD
    Total Remaining to be Sold $0 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    The total offering amount reflects the total gross proceeds to be received assuming cash exercise of all warrants issued in the private placement.

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    1

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $351,897 USD
       Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    The placement agent received a cash placement fee equal to 6.0% of the gross proceeds received from the sale of the securities sold in the registered direct offering and the concurrent private placement, plus expense reimbursement of $100,000.

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    While no offering proceeds are set aside for payments to the named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to executive officers and to paying director stipends.

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    Vicarious Surgical Inc. /s/ Stephen From Stephen From Chief Executive Officer 2025-10-15

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $RBOT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RBOT

    DatePrice TargetRatingAnalyst
    3/4/2022$16.00 → $7.00Overweight → Neutral
    Piper Sandler
    1/7/2022$16.00Outperform
    Credit Suisse
    12/7/2021$15.00Outperform
    Cowen & Co.
    11/5/2021$15.00Buy
    Canaccord Genuity
    10/18/2021$15.00Buy
    BTIG
    10/7/2021$16.00Overweight
    Piper Sandler
    More analyst ratings

    $RBOT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vicarious Surgical Announces Pricing of $5.9 Million Registered Direct Offering

    Vicarious Surgical Inc. (NYSE:RBOT, RBOT.WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, announced today that it has entered into a securities purchase agreement with a single institutional investor to purchase the Company's Class A common stock and pre-funded warrants in a registered direct offering and warrants to purchase its Class A common stock in a concurrent private placement. The combined effective purchase price for one share of Class A common and accompanying warrants to purchase two shares of Class A common stock will be $5.10, and the combined purchase price for one pre-funded warrant and accompanying warrants to purc

    10/8/25 7:00:00 AM ET
    $RBOT
    Industrial Specialties
    Health Care

    Vicarious Surgical Announces Appointment of Joseph Doherty as Chairman of The Board

    Vicarious Surgical Inc. (NYSE:RBOT, RBOT.WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Joseph Doherty as Chairman of the Company's Board of Directors (the "Board"). Mr. Doherty has served as a member of the Board since June 2025. "Since joining Vicarious Surgical, I've had the opportunity to work closely with Joe and greatly value his perspective," said Stephen From, Chief Executive Officer. "As Chairman of the Board, he brings a wealth of experience and thoughtful leadership that will serve the Company well. I look forward to partnering with him and the Board as we advance o

    9/25/25 4:15:00 PM ET
    $JNJ
    $RBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    Vicarious Surgical to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

    Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the Company will participate in the H.C. Wainwright 27th Annual Global Investment Conference in New York. Management is scheduled to present on Wednesday, September 10, 2025 at 9:00 a.m. ET. Interested parties may access a live audio webcast by visiting the "Events & Presentations" section of the company's website at: investor.vicarioussurgical.com About Vicarious Surgical Founded in 2014, Vicarious Surgical is a next generation surgical robotics company, developing a unique disrup

    8/27/25 4:15:00 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    $RBOT
    SEC Filings

    View All

    SEC Form D filed by Vicarious Surgical Inc.

    D - Vicarious Surgical Inc. (0001812173) (Filer)

    10/15/25 4:30:50 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    Vicarious Surgical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - Vicarious Surgical Inc. (0001812173) (Filer)

    10/8/25 5:05:38 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    SEC Form 424B5 filed by Vicarious Surgical Inc.

    424B5 - Vicarious Surgical Inc. (0001812173) (Filer)

    10/8/25 5:04:32 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    $RBOT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Doherty Joseph Edward

    4 - Vicarious Surgical Inc. (0001812173) (Issuer)

    10/2/25 4:20:23 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    SEC Form 3 filed by new insider Doherty Joseph Edward

    3 - Vicarious Surgical Inc. (0001812173) (Issuer)

    10/2/25 4:19:25 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    President Sachs Adam David sold $2,665 worth of shares (463 units at $5.76), decreasing direct ownership by 0.93% to 49,164 units (SEC Form 4)

    4 - Vicarious Surgical Inc. (0001812173) (Issuer)

    9/4/25 4:47:04 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    $RBOT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Vicarious Surgical downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Vicarious Surgical from Overweight to Neutral and set a new price target of $7.00 from $16.00 previously

    3/4/22 4:51:18 AM ET
    $RBOT
    Industrial Specialties
    Health Care

    Credit Suisse initiated coverage on Vicarious Surgical with a new price target

    Credit Suisse initiated coverage of Vicarious Surgical with a rating of Outperform and set a new price target of $16.00

    1/7/22 7:09:02 AM ET
    $RBOT
    Industrial Specialties
    Health Care

    Cowen & Co. initiated coverage on Vicarious Surgical with a new price target

    Cowen & Co. initiated coverage of Vicarious Surgical with a rating of Outperform and set a new price target of $15.00

    12/7/21 7:31:51 AM ET
    $RBOT
    Industrial Specialties
    Health Care

    $RBOT
    Financials

    Live finance-specific insights

    View All

    Vicarious Surgical Reports Second Quarter 2025 Financial Results

    Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the second quarter ended June 30, 2025. Management will host a corresponding conference call at 4:30 p.m. ET today, August 12, 2025. "Leading Vicarious Surgical from its earliest days through key development milestones has been an extraordinary experience. I'm incredibly proud of the foundation we've built. As I move into the role of President, I'm pleased to welcome Stephen as CEO," said Adam Sachs, President, Co-Founder, and Board member. "His depth of experienc

    8/12/25 4:15:00 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    Vicarious Surgical to Report Second Quarter 2025 Financial Results on August 12, 2025

    Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced it will report financial results for the second quarter ended June 30, 2025 after the market closes on Tuesday, August 12, 2025. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing +1 833-470-1428 for domestic callers or +1 404-975-4839 for international callers, using access code: 572850. A live and archived webcast of the event will be available at https://inves

    7/29/25 4:05:00 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    Vicarious Surgical Reports First Quarter 2025 Financial Results

    Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the first quarter ended March 31, 2025. Management will host a corresponding conference call at 4:30 p.m. ET today, May 12, 2025. "Following years of meticulous work to develop and advance our surgical system and proprietary decoupled actuating technology, we are just a few quarters away from our biggest milestone yet - our first clinical patients. 2025 will be the year Vicarious Surgical evolves into a clinical-stage company and demonstrates the immense value of o

    5/12/25 4:05:00 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    $RBOT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Vicarious Surgical Inc. (Amendment)

    SC 13G/A - Vicarious Surgical Inc. (0001812173) (Subject)

    2/13/24 4:36:42 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Vicarious Surgical Inc. (Amendment)

    SC 13G/A - Vicarious Surgical Inc. (0001812173) (Subject)

    8/15/23 10:28:36 AM ET
    $RBOT
    Industrial Specialties
    Health Care

    SEC Form SC 13D/A filed by Vicarious Surgical Inc. (Amendment)

    SC 13D/A - Vicarious Surgical Inc. (0001812173) (Subject)

    8/9/23 5:10:57 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    $RBOT
    Leadership Updates

    Live Leadership Updates

    View All

    Vicarious Surgical Announces Appointment of Joseph Doherty as Chairman of The Board

    Vicarious Surgical Inc. (NYSE:RBOT, RBOT.WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Joseph Doherty as Chairman of the Company's Board of Directors (the "Board"). Mr. Doherty has served as a member of the Board since June 2025. "Since joining Vicarious Surgical, I've had the opportunity to work closely with Joe and greatly value his perspective," said Stephen From, Chief Executive Officer. "As Chairman of the Board, he brings a wealth of experience and thoughtful leadership that will serve the Company well. I look forward to partnering with him and the Board as we advance o

    9/25/25 4:15:00 PM ET
    $JNJ
    $RBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    Vicarious Surgical Announces Appointment of Sarah Romano as Chief Financial Officer

    Ms. Romano brings decades of experience with a strong track record in financial strategy and corporate development Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Sarah Romano as Chief Financial Officer (CFO), effective April 1, 2025. Ms. Romano will oversee Vicarious Surgical's financial strategy, leveraging decades of financial leadership experience in capital markets. With exceptional strategic acumen, Ms. Romano has a proven record of driving growth and value creation in public companies, particularly in the h

    3/13/25 8:30:00 AM ET
    $RBOT
    Industrial Specialties
    Health Care

    Vicarious Surgical Strengthens Executive Team with Appointment of Randy Clark as Company President

    Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS))), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced that Randy Clark has been appointed President effective today, January 29, 2024. As Vicarious Surgical prepares for its next phase of growth following the anticipated finalization of the Vicarious Surgical Version 1.0 System ("V1.0"), the newly established role of President is designed to fortify organizational alignment and focus on the Company's long-term needs and objectives. Reporting to Chief Executive Officer Adam Sachs, Mr. Clark will a

    1/29/24 8:30:00 AM ET
    $RBOT
    Industrial Specialties
    Health Care